Georgia  Erbez net worth and biography

Georgia Erbez Biography and Net Worth

Georgia L. Erbez joined Harpoon in October 2018 as Chief Financial Officer, bringing financial, operational and strategic advisory experience in multiple biotech settings, as well as investment banking. She previously served as Chief Business Officer and Chief Financial Officer of Zosano Pharma, a therapeutics company focused on migraine. She served as Chief Financial Officer and Executive Vice President of Asterias Biotherapeutics and Chief Financial Officer, Secretary and Treasurer of Raptor Pharmaceuticals, where she helped to navigate the company through a growth period that included its first drug approval and subsequent commercial launch. Prior to Raptor, Ms. Erbez was a Managing Director, Healthcare Investment Banking at Collins Stewart, a Founder and Managing Director at Beal Advisors, and a senior level investment banker at Jefferies & Company, Inc. and Cowen and Company. She has also held positions at the investment banks Hambrecht & Quist and Alex. Brown & Sons Inc. Ms. Erbez currently serves as a member of the Board of Directors of Altibio, Inc, Sierra Oncology (Nasdaq: SRRA) and Neurana Pharmaceuticals. Ms. Erbez received a Bachelor of Arts degree, International Relations from the University of California at Davis.

What is Georgia Erbez's net worth?

The estimated net worth of Georgia Erbez is at least $108,814.29 as of August 18th, 2020. Ms. Erbez owns 4,729 shares of Harpoon Therapeutics stock worth more than $108,814 as of March 29th. This net worth estimate does not reflect any other investments that Ms. Erbez may own. Learn More about Georgia Erbez's net worth.

How do I contact Georgia Erbez?

The corporate mailing address for Ms. Erbez and other Harpoon Therapeutics executives is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Harpoon Therapeutics can also be reached via phone at (650) 443-7400 and via email at [email protected]. Learn More on Georgia Erbez's contact information.

Has Georgia Erbez been buying or selling shares of Harpoon Therapeutics?

Georgia Erbez has not been actively trading shares of Harpoon Therapeutics during the last ninety days. Most recently, on Wednesday, September 22nd, Georgia Erbez bought 1,030 shares of Harpoon Therapeutics stock. The stock was acquired at an average cost of $81.00 per share, with a total value of $83,430.00. Learn More on Georgia Erbez's trading history.

Who are Harpoon Therapeutics' active insiders?

Harpoon Therapeutics' insider roster includes Georgia Erbez (CFO), Ansbert Gadicke (Major Shareholder), and Holger Wesche (Insider). Learn More on Harpoon Therapeutics' active insiders.

Are insiders buying or selling shares of Harpoon Therapeutics?

In the last twelve months, Harpoon Therapeutics insiders bought shares 1 times. They purchased a total of 21,397,205 shares worth more than $492,135,715.00. The most recent insider tranaction occured on March, 11th when Major Shareholder Merck & Co., Inc. bought 21,397,205 shares worth more than $492,135,715.00. Insiders at Harpoon Therapeutics own 17.0% of the company. Learn More about insider trades at Harpoon Therapeutics.

Information on this page was last updated on 3/11/2024.

Georgia Erbez Insider Trading History at Harpoon Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/22/2021Buy1,030$81.00$83,430.00View SEC Filing Icon  
8/18/2020Buy209$116.00$24,244.004,729View SEC Filing Icon  
7/31/2020Buy181$109.20$19,765.204,729View SEC Filing Icon  
1/21/2020Buy670$140.90$94,403.004,729View SEC Filing Icon  
See Full Table

Georgia Erbez Buying and Selling Activity at Harpoon Therapeutics

This chart shows Georgia Erbez's buying and selling at Harpoon Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Harpoon Therapeutics Company Overview

Harpoon Therapeutics logo
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Read More

Today's Range

Now: $23.01
Low: $22.99
High: $23.02

50 Day Range

MA: $22.71
Low: $22.31
High: $23.01

2 Week Range

Now: $23.01
Low: $3.11
High: $23.21

Volume

6,624,300 shs

Average Volume

1,516,200 shs

Market Capitalization

$389.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.11